Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00972933 · ClinicalTrials.gov registry record · Early Phase 1
Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma
A Early Phase 1 study, sponsored by Diwakar Davar.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 59
- Enrollment target
NCT00972933: Completed Early Phase 1 study, sponsored by Diwakar Davar.
NCT00972933 is a Early Phase 1 study that has completed, run by Diwakar Davar. The registered enrollment target is 59 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (11% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00972933, a Early Phase 1 study, has completed, sponsored by Diwakar Davar.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 59 participants
- Enrollment target
Study Summary
Ipilimumab is a manufactured monoclonal antibody, much like the antibodies usually made by the human body to fight off infection; however it is not known why the human body does not "fight off" a cancerous tumor. The idea behind developing this experimental drug is to stimulate the immune system to make antibodies to kill cancer cells. This research study is considered "experimental" because it has not received approval from the Food and Drug Administration (FDA) for the treatment of this type of cancer. This monoclonal antibody has been specifically made to block Cytotoxic T Lymphocyte Antigen 4 (CTLA4), which is a protein found on cells of the immune system. CTLA4 seems to slow down the immune response, so blocking it with an anti-CTLA4 antibody may make the immune response more active. The purpose of this study is to see if Ipilimumab affects the response of the patient's immune system toward their cancer.
Interventions
- DRUG ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2009-12 |
| Est. Completion | 2017-09-26 |
| Phase | Early Phase 1 |
What the finished NCT00972933 record still lists
NCT00972933 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (11% higher).
The record links to 0 conditions, and to 1 intervention - of which ipilimumab is the first listed.
NCT00972933 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00972933 about?
NCT00972933 is a clinical study titled "Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma". Ipilimumab is a manufactured monoclonal antibody, much like the antibodies usually made by the human body to fight off infection; however it is not known why the human body does not "fight off" a cancerous tumor. The idea behind developing this experimental drug is to stimulate the immune system to ...
What is the current status of trial NCT00972933?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 59 participants. The study started on 2009-12. Estimated completion is 2017-09-26.
What interventions are being tested in trial NCT00972933?
The interventions under investigation include: ipilimumab (DRUG).
Who is sponsoring clinical trial NCT00972933?
This trial is sponsored by Diwakar Davar, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00972933's enrollment target sits among peer trials
59 437th of 2000 higher than 1,561 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia